Bellicum Pharma (BLCM) Misses Q2 EPS by 4c

Bellicum Pharma (NASDAQ: BLCM) reported Q2 EPS of ($0.61), $0.04 worse than the analyst estimate of ($0.57).

For earnings history and earnings-related data on Bellicum Pharma (BLCM) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Deutsche Bank Starts DexCom (DXCM) at Buy
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus